ST. JOSEPH, Mich., March 13 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that they have been awarded a 2006 competitive strategy and bioinformatics outsourcing leadership award from Frost & Sullivan, competing with 150 other companies in Life sciences. Frost & Sullivan cited that GeneGo’s innovative competitive strategy had yielded significant market gains and their analysts expect such innovations will produce lasting, precedent setting trends. This information was gathered by interviews with the experts in the field, end users and the companies themselves. Frost & Sullivan also state that GeneGo is ahead in terms of innovativeness and product quality and has the unique ability to cover the whole spectrum of systems biology that other companies miss.
“The reason why GeneGo Inc.'s competitive approach in the Bioinformatics market has been considered successful is because this makes the company appear attractive in terms of profitability, sustained commercial viability and technical competence,” says Frost & Sullivan Analyst Sumitha Kannan. “The scientific community perceives the company as having a clear vision of its needs and a strategic focus on potential future growth areas.”
“We are honored to receive this award and understand its importance in this competitive field. This award is yet another validation of the high standards that GeneGo sets in the systems biology and pharmacology field,” said Julie Bryant, GeneGo’s VP of Business development. “We would also like to acknowledge help and support from our customers and partners whose feedback is really important in our product development.”
To download the white paper please go to www.genego.com.
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 4.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug2.0(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company’s web site at www.genego.com
MetaCore(TM), MetaBase(TM) MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM), 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
GeneGo, Inc.
CONTACT: Julie Bryant, VP Business Development and Marketing, GeneGo,Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
